Anthem Biosciences Ltd.
NSE: ANTHEM · Biotechnology
Snapshot
Unlock Anthem Biosciences Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Anthem Biosciences is a technology-focused contract research, development, and manufacturing organisation (CRDMO) providing end-to-end solutions for new chemical and biological entities. The company specialises in complex fermentation-based APIs, peptides, and advanced biotherapeutics, supporting clients from target identification through to commercial manufacturing.
Business Model
The company generates revenue through a dual-segment model comprising CRDMO services for pharmaceutical and biotech partners and the direct sale of speciality ingredients, including enzymes, probiotics, and APIs. It leverages advanced technical capabilities in flow chemistry, biosynthesis, and fermentation to provide high-value manufacturing services.
- Incorporation Year:2006
Growth Outlook
Growth is driven by the expansion of its manufacturing capabilities in high-growth areas such as RNA-based therapies, antibody-drug conjugates, and complex peptides. The company continues to scale its fermentation and biotransformation infrastructure to meet the increasing global demand for biosimilars and specialised nutritional actives.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from global health authorities, where any failure to maintain quality standards could disrupt manufacturing operations.
- Intellectual Property Risk. As a contract research organisation, the company must maintain robust data security and IP protection protocols to retain client trust and competitive advantage.
- Technological Obsolescence. Rapid advancements in biotechnology require continuous capital expenditure to upgrade facilities and maintain state-of-the-art manufacturing capabilities.
- Client Concentration. Reliance on a limited number of pharmaceutical partners for large-scale manufacturing contracts may expose the company to revenue volatility if specific projects are terminated.
Start your research today
Unlock AI insights, financials, peers and live data on Anthem Biosciences Ltd. and 5,000+ companies — free.
Key Metrics
P/E
136.0x
Q1 FY27 · consolidated
EV/EBITDA
55.1x
Q1 FY27 · consolidated
NET PROFIT MARGIN
28.7%
Q1 FY27 · consolidated
DEBT TO EQUITY
1.2%
Q1 FY27 · consolidated
Peers · Biotechnology
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Anthem Biosciences Ltd.ANTHEM | ₹52,605 Cr | 135.96 | 55.10 | — | 47.5% | 18.9% | 25.4% | +10.7% |
Advanced Enzyme Technologies LimitedADVENZYMES | ₹3,283 Cr | 19.78 | 12.17 | 12.2% | 35.0% | 11.3% | 14.3% | -14.3% |
As of Q1 FY27
Financials
Anthem Biosciences Ltd.
NSE: ANTHEM · Biotechnology
Snapshot
Unlock Anthem Biosciences Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Anthem Biosciences is a technology-focused contract research, development, and manufacturing organisation (CRDMO) providing end-to-end solutions for new chemical and biological entities. The company specialises in complex fermentation-based APIs, peptides, and advanced biotherapeutics, supporting clients from target identification through to commercial manufacturing.
Business Model
The company generates revenue through a dual-segment model comprising CRDMO services for pharmaceutical and biotech partners and the direct sale of speciality ingredients, including enzymes, probiotics, and APIs. It leverages advanced technical capabilities in flow chemistry, biosynthesis, and fermentation to provide high-value manufacturing services.
- Incorporation Year:2006
Growth Outlook
Growth is driven by the expansion of its manufacturing capabilities in high-growth areas such as RNA-based therapies, antibody-drug conjugates, and complex peptides. The company continues to scale its fermentation and biotransformation infrastructure to meet the increasing global demand for biosimilars and specialised nutritional actives.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from global health authorities, where any failure to maintain quality standards could disrupt manufacturing operations.
- Intellectual Property Risk. As a contract research organisation, the company must maintain robust data security and IP protection protocols to retain client trust and competitive advantage.
- Technological Obsolescence. Rapid advancements in biotechnology require continuous capital expenditure to upgrade facilities and maintain state-of-the-art manufacturing capabilities.
- Client Concentration. Reliance on a limited number of pharmaceutical partners for large-scale manufacturing contracts may expose the company to revenue volatility if specific projects are terminated.
Start your research today
Unlock AI insights, financials, peers and live data on Anthem Biosciences Ltd. and 5,000+ companies — free.
Key Metrics
P/E
136.0x
Q1 FY27 · consolidated
EV/EBITDA
55.1x
Q1 FY27 · consolidated
NET PROFIT MARGIN
28.7%
Q1 FY27 · consolidated
DEBT TO EQUITY
1.2%
Q1 FY27 · consolidated
Peers · Biotechnology
As of Q1 FY27